Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - coated tablet - 20 mg

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - coated tablet - 40 mg

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - soft gelatin capsule

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - coated tablet - 40 mg

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - syrup - 0.9 gm/100ml

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - coated tablet - 300 mg

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt - injection - 250 mg

Египат - Енглески - EDA (Egyptian Drug Authority)

novartis pharma egypt. -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).